Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Institutional Investors Sentiment Index Crashed in 2018 Q1

June 14, 2018 - By Darrin Black

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Logo

Sentiment for Rigel Pharmaceuticals Inc (NASDAQ:RIGL)

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) institutional sentiment decreased to 1.23 in Q1 2018. Its down -0.83, from 2.06 in 2017Q4. The ratio dived, as 49 institutional investors opened new and increased holdings, while 40 reduced and sold stock positions in Rigel Pharmaceuticals Inc. The institutional investors in our partner’s database reported: 126.59 million shares, down from 127.13 million shares in 2017Q4. Also, the number of institutional investors holding Rigel Pharmaceuticals Inc in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 13 Reduced: 27 Increased: 35 New Position: 14.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $547.18 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

The stock increased 1.67% or $0.055 during the last trading session, reaching $3.345. About 2.36 million shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 61.57% since June 14, 2017 and is uptrending. It has outperformed by 49.00% the S&P500.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 7. They expect $-0.16 earnings per share, 0.00 % or $0.00 from last year’s $-0.16 per share. After $-0.17 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.88 % EPS growth.

Dafna Capital Management Llc holds 1.55% of its portfolio in Rigel Pharmaceuticals, Inc. for 901,933 shares. Rhenman & Partners Asset Management Ab owns 1.62 million shares or 0.71% of their US portfolio. Moreover, Nea Management Company Llc has 0.51% invested in the company for 3.24 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.39% in the stock. J. Goldman & Co Lp, a New York-based fund reported 832,500 shares.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $20,550 activity.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Ratings analysis reveals 100% of Rigel Pharmaceuticals’s analysts are positive. Out of 6 Wall Street analysts rating Rigel Pharmaceuticals, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $500 while the high is $10. The stock’s average target of $7.50 is 124.22% above today’s ($3.345) share price. RIGL was included in 15 notes of analysts from December 15, 2017. The company was maintained on Wednesday, May 2 by BMO Capital Markets. On Wednesday, April 4 the stock rating was maintained by Jefferies with “Buy”. On Tuesday, May 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Tuesday, March 6. Cantor Fitzgerald has “Buy” rating and $7.0 target. The company was maintained on Wednesday, March 7 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, April 3 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, May 2 by H.C. Wainwright. As per Friday, February 2, the company rating was maintained by H.C. Wainwright. Piper Jaffray initiated Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Thursday, December 21 with “Buy” rating. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by Cantor Fitzgerald on Tuesday, April 17.

More important recent Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news were published by: Seekingalpha.com which released: “Reader Inquiry: Is Rigel Pharmaceuticals Due For A Near Term Breakout?” on June 11, 2018, also Benzinga.com published article titled: “32 Stocks Moving In Monday’s Mid-Day Session”, Benzinga.com published: “44 Biggest Movers From Yesterday” on June 12, 2018. More interesting news about Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) was released by: Streetinsider.com and their article: “Rigel Pharma (RIGL) to Present Phase 2 Results for Fostamatinib in AIHA at EHA Meeting” with publication date: June 12, 2018.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: